T. Nomura et al., PHARMACOKINETIC CHARACTERISTICS AND THERAPEUTIC EFFECTS OF MITOMYCIN-C DEXTRAN CONJUGATES AFTER INTRATUMORAL INJECTION, Journal of controlled release, 52(3), 1998, pp. 239-252
The pharmacokinetics and therapeutic effects of macromolecular prodrug
s of mitomycin C (MMC), MMC-dextran conjugates (MMC-D) were studied af
ter intratumoural injection in rats bearing Walker 256 carcinosarcoma.
As the first step, the intratumoural disposition characteristics of t
hese drugs were delineated in perfusion experiments employing a tissue
-isolated tumour preparation. While MMC immediately disappeared from t
he tumour preparation following direct intratumoural injection, cation
ic and anionic MMC-D were retained in the tumour longer, demonstrating
that the intratumoural clearance of MMC can be greatly retarded by de
xtran conjugation. The effect was more pronounced in the case of the c
ationic conjugate, Venous outflow data in the perfusion experiments we
re analyzed based on a compartment model in which the tumour tissue wa
s assumed to consist of two compartments, one well- and the other poor
ly-perfused. The pharmacokinetic analysis revealed that macromolecular
conjugation reduced elimination of MMC from the poorly-perfused regio
n rather than well-perfused region, Simulation of conjugated and free
MMC levels in the tissue using the calculated parameters clearly showe
d that intratumoural injection of MMC-D, especially the cationic form,
can maintain a certain level of active free MMC in the tissue for a m
uch longer time period. The long retention of cationic MMC-D in tumour
after intratumoural injection was also confirmed by an in vivo pharma
cokinetic study and whole body autoradiography in rats bearing subcuta
neous Walker 256 carcinosarcoma. In addition, superior antitumour acti
vity of cationic MMC-D was observed against subcutaneous rumours after
intratumoural injection. Together with the finding that MMC is select
ively toxic to hypoxic tumour cells at low concentrations, these pharm
acokinetic studies strongly support the therapeutic efficacy of the ma
cromolecular prodrugs. (C) 1998 Elsevier Science B.V.